Monoclonal Antibody Therapeutic Target Protein

Development of therapeutic monoclonal antibodies has been growing in cancer and autoimmune disease and is rapidly expanding into new therapeutic areas. The total number of monoclonal antibody drugs (including drugs withdrawn for various reasons after approval) has exceeded 70. In the process of therapeutic monoclonal antibody development, target protein reagent functions a lot, from antibody preparation, clone screening to drug assay. Sino Biological Inc. possesses abundant recombinant protein production and antibody drug development experience, so we can provide you high-quality monoclonal antibody therapeutic target proteins for your drug development.

Hot Monoclonal Antibody Therapeutic Targets

Validated Application in Citations for Monoclonal Antibody Therapeutic Targets

Affinity SPR study of nanobodys interacting with mouse PD-L1 protein

Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
Authors: Broos K, et al.
Journal: Oncotarget

Affinity/kinetics SPR study of purified nanobodys interacting with immobilized His-tagged recombinant mouse PD-L1 protein (Cat. No. 50010-M08H). The KD values are in the low nanomolar range as shown in the image.

Fig. 1 Affinity/kinetics SPR study of purified nanobodys interacting with immobilized His-tagged recombinant mouse PD-L1 protein (Cat. No. 50010-M08H). The KD values are in the low nanomolar range as shown in the image.
Nbs were raised against mouse PD-L1 by immunization of a dromedary with the PD-L1 expressing mouse macrophage cell line RAW264.7. Thirty-seven Nbs were selected after screening of an immune phage library on recombinant mouse PD-L1. After binding assay through ELISA, SPR and FCM, Nbs C3, C7, E2 and E4 were chosen for further evaluation. The selected anti-PD-L1 and control Nbs were then produced and purified as C-terminally His6-tagged proteins from E. coli fermentation cultures. The affinity (KD) of the purified Nbs for the immobilized mouse PD-L1 antigen was determined using SPR.

Binding affinities study of variant antibodies using human CD22 protein

Title: Antibody Specific for CD22 and Methods of Use
Authors: Rabuka D, et al.
Journal: US 9,181,343 B2

Kon Koff Kd
V12 4.93E+05 9.85E-05 2.00E-10
V13 3.38E+05 1.32E-04 3.90E-10
V14 3.92E+05 2.40E-04 6.14E-10
V15 4.31E+05 2.15E-04 4.97E-10
V16 3.68E+05 1.73E-04 4.71E-10
V17 3.39E+05 2.52E-04 7.42E-10
V18 3.26E+05 1.87E-04 5.72E-10
V19 3.63E+05 2.01E-04 5.53E-10
V20 4.01E+05 2.76E-04 6.89E-10

Table. 1 Binding affinities of variant antibodies to were determined toward the human CD22(Cat. No. 11958-H08H) and the Kd were determined
Human CD22 was biotinylated to Lys using a LC-biotin. The binding of antibodies (variants 12 through 20) to human CD22 was measured using a ForteBio instrument. StreptAvidin derivatized ForteBio bio sensors were loaded with the biotinylated human CD22 molecules. The concentrations of the antibodies of interest were confirmed by A280 and loaded biosensors were exposed to increasing concentrations of each of the antibodies. The kinetic association and dissociation rates were determined toward the human CD22 at 4-5 concentrations at pH 7.25 and the Kd were determined.

Monoclonal Antibody Therapeutic Target Protein Advantages

High purity, most>95% as determined by SDS-PAGE

The purity of human EGFR protein (Cat. No. 10001-H02H) is >97% as determined by SDS-PAGE.
Fig. 1 The purity of human EGFR protein (Cat. No. 10001-H02H) is >97% as determined by SDS-PAGE.
The purity of human DLL4 protein (Cat. No. 10171-HCCH) is >95% as determined by SDS-PAGE.
Fig. 2 The purity of human DLL4 protein (Cat. No. 10171-HCCH) is >95% as determined by SDS-PAGE.

Validated high binding activity

The human PD-1 protein (Cat. No. 10377-H08H) binds two PD-1 antibody drugs in functional ELISAs.
Fig. 3 The human PD-1 protein (Cat. No. 10377-H08H) binds two PD-1 antibody drugs in functional ELISAs.
The human CD20 protein (Cat. No. 11007-H34E) binds CD20 antibody drugs in a functional ELISA.
Fig. 4 The human CD20 protein (Cat. No. 11007-H34E) binds CD20 antibody drugs in a functional ELISA.

Low endotoxin: < 1.0 EU/μg by the LAL method

Biotinylated proteins available

Sino Biological provide ready-to-use biotinylated proteins for most of the monoclonal antibody therapeutic targets, all of which go through strict QC standard and show high activity. To learn more about biotinylated proteins.

Custom recombinant protein expression and purification service

If you can not find the protein you need, we also offer custom service for protein production. With five protein expression systems and over 10 years experience, we are professional in recombinant protein produciton. To find more ……

Contact us
Tel: 215-583-7898
Mail: order@sinobiological.com
Recombinant protein homepage
• Immune checkpoint proteins
• Biotinylated proteins
• CAR-T cell therapy target proteins
• Fc receptors
• Cytokines
Other Elite Reagents
One-stop CAR-T reagents
Antibodies
• IHC antibody
• Elite Rabbit Mab
• ELISA kits
cDNA clones & Others
• GFP & OFP tagged cDNA clone
• Lentiviral ORF clone / plasmid
• Transfection reagents
• Protease & Nuclease